Metformin functions through a gut microbiome–bile acid–farnesoid X receptor axis to lower glucose in type 2 diabetes, revealing a new therapeutic target in this disease.
References
Sterne, J. Maroc Med. 36, 1295–1296 (1957).
Karlsson, F. H. et al. Nature 498, 99 (2013).
Napolitano, A. et al. PLoS ONE 9, e100778 (2014).
Sun, L. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0222-4 (2018).
Chow, M. D., Lee, Y.-H. & Guo, G. L. Mol. Aspects Med. 56, 34–44 (2017).
Chiang, J. Y. L. et al. Dig. Dis. 35, 241–245 (2017).
Foretz, M. et al. J. Clin. Invest. 120, 2355–2369 (2010).
Mueller, M. et al. J. Hepatol. 62, 1398–1404 (2015).
Lindor, K. D. et al. Hepatology 39, 770–778 (2004).
Fang, S. et al. Nat. Med. 21, 159–165 (2015).
Pathak, P. et al. Hepatology 68, 1574–1588 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Guo, G.L., Xie, W. Metformin action through the microbiome and bile acids. Nat Med 24, 1789–1790 (2018). https://doi.org/10.1038/s41591-018-0273-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0273-6
- Springer Nature America, Inc.
This article is cited by
-
Gut Microbiota Dysbiosis in Human Obesity: Impact of Bariatric Surgery
Current Obesity Reports (2019)